After a hectic work schedule and a gap of more than two months we are back to our regular blogging. We sincerely apologize to our readers that we abruptly stopped postings without intimidating about our temporary break. However, it is always great to be back in action. We lastly left our discussion on section 3(d) incomplete which we will surely be completing in our coming posts. We will also try to cover and analyze some of recent happenings in Indian patent scenario in particularly Tenofovir patent application rejection, update on Tarceva patent dispute and Bayer Sorafenib patent decision. So let enjoy blogging again and look forward to great discussions ahead.
No comments:
Post a Comment